Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

In a study recently published in Cancer Research, Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC); this protein could also serve as part of a treatment strategy to stop the spread of the disease.

15 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Second course of treatment could cure head and neck cancer

A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer.

13 Jun 2011

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Hundreds of surfers, cancer survivors and friends will gather together, with surfboards in hand, on La Jolla Shores Sunday, June 19 for an annual San Diego tradition: Survivor Beach. Attendees will place surfboards along the edge of the shore, nose-to-tail, from Scripps Pier down La Jolla Shores, with the goal of forming a record-breaking line of several hundred surfboards.

13 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

CEL-SCI Corporation today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM H1N1 activated dendritic cells to treat the H1N1 virus.

27 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

The American Society for Radiation Oncology has selected K. Kian Ang, MD, PhD, FASTRO, and Bernard Cummings, MB, ChB, FASTRO, as the Society's 2011 Gold Medal recipients.

26 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

VA develops FATE survey to access treatment quality at the end of patients' lives

Though there have been significant improvements in the treatment of head and neck cancer, there is still a lack of data on the experience of end of life care for head and neck cancer patients, according to a new study published in the May 2011 issue of Otolaryngology-Head and Neck Surgery.

2 May 2011

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Combining computerized tomography with fluorodeoxyglucose positron emission tomography images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta.

30 Apr 2011

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

CEL-SCI Corporation announced today that the Biologics and Genetic Therapeutics Directorate of Health Canada has issued a final "no objection" letter for CEL-SCI to be able to begin enrollment of patients for a Phase III clinical trial of Multikine in Canada.

30 Apr 2011

Head and Neck Cancer News and Research

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

IsoRay announces combination therapy study for prostate cancer

RHEI receives Chinese SFDA acceptance letter for MuGard

VARI researchers discover protein linked to spread of head and neck cancer nasopharyngeal carcinoma

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Second course of treatment could cure head and neck cancer

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

NYU Cancer Institute scientists present new research findings at ASCO 2011

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

VA develops FATE survey to access treatment quality at the end of patients' lives

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

CEL-SCI receives no objection letter to initiate Phase III clinical trial of Multikine in Canada

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News